Existing users Log In New users Sign up


TSP-1 mediates breast cancer cell migration

DISCOVERIES (ISSN 2359-7232), 2014, October-December

CITATION: 

Ndishabandi D, Duquette C, Billah GE, Reyes M, Duquette M, Lawler J, Kazerounian S. Thrombospondin-1 Modulates Actin Filament Remodeling and Cell Motility in Mouse Mammary Tumor cells in Vitro. Discoveries 2014, Oct-Dec; 2(4): e31. DOI: 10.15190/d.2014.23

Submitted: July 25, 2014; Revised: September 9, 2014; Accepted: September 18, 2014; Published: October 8, 2014; 

GO BACK to 2014, October-December issue 
GO BACK to DISCOVERIES

Thrombospondin-1 Modulates Actin Filament Remodeling and Cell Motility in Mouse Mammary Tumor cells in Vitro

Dorothy Ndishabandi, Cameron Duquette, Ghita El-Moatassim Billah, Millys Reyes, Mark Duquette, Jack Lawler, Shideh Kazerounian*

(1) Department of Medicine, Division of Genetics, Boston Children’s Hospital, Boston, MA; 

(2) Department of Pathology, Division of Experimental Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA

*Correspondence toShideh Kazerounian, Ph.D., Department of Pediatrics, Division of Genetics, Boston Children's Hospital, Harvard Medical School, 3 BlackFan Circle, Center for Life Sciences, Boston, MA 02115; Phone: (617)355-7748; Fax: (617)730-0253; E-mail: shideh.kazerounian@childrens.harvard.edu

Abstract

It is well established that the secretion of thrombospondin-1 (TSP-1) by activated stromal cells and its accumulation in the tumor microenvironment during dysplasia inhibits primary tumor growth through inhibition of angiogenesis. This inhibitory function of TSP-1 is actuated either by inhibiting MMP9 activation and the release of VEGF from extracellular matrix or by an interaction with CD36 on the surface of endothelial cells resulting in an increase in apoptosis. In contrast, several published articles have also shown that as tumor cells become more invasive and enter the early stage of carcinoma, they up-regulate TSP-1 expression, which may promote invasion and migration. In our in vivo studies using the polyoma middle T antigen (PyT) transgenic mouse model of breast cancer, we observed that the absence of TSP-1 significantly increased the growth of primary tumors, but delayed metastasis to the lungs. In this study, we propose a mechanism for the pro-migratory function of TSP-1 in mouse mammary tumor cells in vitro. We demonstrate a correlation of TSP-1 expression and its receptor integrin 3β1, which is considered a pro-migratory protein in cancer cells. In addition we propose that binding of TSP-1 to integrin α3β1 is important for mediating actin filament polymerization and therefore, cell motility.  These findings can help explain the dual functionality of TSP-1 in cancer progression.

Access full text of the manuscript here: 

References:

1. Albo D, Berger DH, Wang TN, Hu X, Rothman V, Tuszynski GP. Thrombospondin-1 and transforming growth factor-beta l promote breast tumor cell invasion through up-regulation of the plasminogen/plasmin system. Surgery 1997; 122: 493-499; discussion 499-500.

2. Albo D, Rothman VL, Roberts DD, Tuszynski GP. Tumour cell thrombospondin-1 regulates tumour cell adhesion and invasion through the urokinase plasminogen activator receptor. Br J Cancer 2000; 83: 298-306.

3. Bein K, Simons M. Thrombospondin type 1 repeats interact with matrix metalloproteinase 2. Regulation of metalloproteinase activity. J Biol Chem 2000; 275: 32167-32173.

4. Bujak E, Pretto F, Ritz D, Gualandi L, Wulhfard S, Neri D. Monoclonal antibodies to murine thrombospondin-1 and thrombospondin-2 reveal differential expression patterns in cancer and low antigen expression in normal tissues. Exp Cell Res 2014.

5. Choma DP, Milano V, Pumiglia KM, DiPersio CM. Integrin alpha3beta1-dependent activation of FAK/Src regulates Rac1-mediated keratinocyte polarization on laminin-5. J Invest Dermatol 2007; 127: 31-40.

6. Clezardin P, Frappart L, Clerget M, Pechoux C, Delmas PD. Expression of thrombospondin (TSP1) and its receptors (CD36 and CD51) in normal, hyperplastic, and neoplastic human breast. Cancer Res 1993; 53: 1421-1430.

7. Danielson KG, Oborn CJ, Durban EM, Butel JS, Medina D. Epithelial mouse mammary cell line exhibiting normal morphogenesis in vivo and functional differentiation in vitro. Proc Natl Acad Sci U S A 1984; 81: 3756-3760.

8. Dawson DW, Pearce SF, Zhong R, Silverstein RL, Frazier WA, Bouck NP. CD36 mediates the In vitro inhibitory effects of thrombospondin-1 on endothelial cells. J Cell Biol 1997; 138: 707-717.

9. Dixit VM, Grant GA, Frazier WA, Santoro SA. Isolation of the fibrinogen-binding region of platelet thrombospondin. Biochem Biophys Res Commun 1984; 119: 1075-1081.

10. Dixit VM, Grant GA, Santoro SA, Frazier WA. Isolation and characterization of a heparin-binding domain from the amino terminus of platelet thrombospondin. J Biol Chem 1984; 259: 10100-10105.

11. Duquette M, Sadow PM, Lawler J, Nucera C. Thrombospondin-1 Silencing Down-Regulates Integrin Expression Levels in Human Anaplastic Thyroid Cancer Cells with BRAF(V600E): New Insights in the Host Tissue Adaptation and Homeostasis of Tumor Microenvironment. Front Endocrinol (Lausanne) 2013; 4: 189.

12. Elzie CA, Murphy-Ullrich JE. The N-terminus of thrombospondin: the domain stands apart. Int J Biochem Cell Biol 2004; 36: 1090-1101.

13. Faulstich H, Zobeley S, Rinnerthaler G, Small JV. Fluorescent phallotoxins as probes for filamentous actin. J Muscle Res Cell Motil 1988; 9: 370-383.

14. Firlej V, Mathieu JR, Gilbert C, Lemonnier L, Nakhle J, Gallou-Kabani C et al. Thrombospondin-1 triggers cell migration and development of advanced prostate tumors. Cancer Res 2011; 71: 7649-7658.

15. Fukushima Y, Ohnishi T, Arita N, Hayakawa T, Sekiguchi K. Integrin alpha3beta1-mediated interaction with laminin-5 stimulates adhesion, migration and invasion of malignant glioma cells. Int J Cancer 1998; 76: 63-72.

16. Isenberg JS, Shiva S, Gladwin M. Thrombospondin-1-CD47 blockade and exogenous nitrite enhance ischemic tissue survival, blood flow and angiogenesis via coupled NO-cGMP pathway activation. Nitric Oxide 2009; 21: 52-62.

17 Jayachandran A, Anaka M, Prithviraj P, Hudson C, McKeown SJ, Lo PH et al. Thrombospondin 1 promotes an aggressive phenotype through epithelial-to-mesenchymal transition in human melanoma. Oncotarget 2014; 5: 5782-5797.

18. Kazerounian S, Yee KO, Lawler J. Thrombospondins: from structure to therapeutics : Thrombospondins in cancer. Cell Mol Life Sci 2008; 65: 700-712.

19. Lai D, Ma L, Wang F. Fibroblast activation protein regulates tumor-associated fibroblasts and epithelial ovarian cancer cells. Int J Oncol 2012; 41: 541-550.

20. Lawler J, Derick LH, Connolly JE, Chen JH, Chao FC. The structure of human platelet thrombospondin. J Biol Chem 1985; 260: 3762-3772.

21. Lawler J. The structural and functional properties of thrombospondin. Blood 1986; 67: 1197-1209.

22. Lawler J. The functions of thrombospondin-1 and-2. Curr Opin Cell Biol 2000; 12: 634-640.

23. Lawler J. Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth. J Cell Mol Med 2002; 6: 1-12.

24. Lawler J, Detmar M. Tumor progression: the effects of thrombospondin-1 and -2. Int J Biochem Cell Biol 2004; 36: 1038-1045.

25. Lawler J. Thrombospondins. Curr Drug Targets 2008; 9: 820-821.

26. Mitchell K, Svenson KB, Longmate WM, Gkirtzimanaki K, Sadej R, Wang X et al. Suppression of integrin alpha3beta1 in breast cancer cells reduces cyclooxygenase-2 gene expression and inhibits tumorigenesis, invasion, and cross-talk to endothelial cells. Cancer Res 2010; 70: 6359-6367.

27. Morini M, Mottolese M, Ferrari N, Ghiorzo F, Buglioni S, Mortarini R et al. The alpha 3 beta 1 integrin is associated with mammary carcinoma cell metastasis, invasion, and gelatinase B (MMP-9) activity. Int J Cancer 2000; 87: 336-342.

28. Nucera C, Porrello A, Antonello ZA, Mekel M, Nehs MA, Giordano TJ et al. B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression. Proc Natl Acad Sci U S A 2010; 107: 10649-10654.

29. Resovi A, Pinessi D, Chiorino G, Taraboletti G. Current understanding of the thrombospondin-1 interactome. Matrix biology : journal of the International Society for Matrix Biology 2014.

30. Rodriguez-Manzaneque JC, Lane TF, Ortega MA, Hynes RO, Lawler J, Iruela-Arispe ML. Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc Natl Acad Sci U S A 2001; 98: 12485-12490.

31. Small JV, Zobeley S, Rinnerthaler G, Faulstich H. Coumarin-phalloidin: a new actin probe permitting triple immunofluorescence microscopy of the cytoskeleton. J Cell Sci 1988; 89 ( Pt 1): 21-24.

32. Stenina-Adognravi O. Thrombospondins: old players, new games. Curr Opin Lipidol 2013; 24: 401-409.

33. Stenina-Adognravi O. Invoking the Power of Thrombospondins: Regulation of Thrombospondins Expression. Matrix biology : journal of the International Society for Matrix Biology 2014.

34. Wang TN, Qian X, Granick MS, Solomon MP, Rothman VL, Berger DH et al. Thrombospondin-1 (TSP-1) promotes the invasive properties of human breast cancer. J Surg Res 1996; 63: 39-43.

35. Wang TN, Qian XH, Granick MS, Solomon MP, Rothman VL, Berger DH et al. Inhibition of breast cancer progression by an antibody to a thrombospondin-1 receptor. Surgery 1996; 120: 449-454.

36. Yee KO, Duquette M, Ludlow A, Lawler J. Purification and analysis of thrombospondin-1. Curr Protoc Cell Biol 2003; Chapter 10: Unit 10 10.

37. Yee KO, Connolly CM, Duquette M, Kazerounian S, Washington R, Lawler J. The effect of  thrombospondin-1 on breast cancer metastasis. Breast Cancer Res Treat 2009; 114: 85-96.

38. Ziober BL, Kramer RH. Identification and characterization of the cell type-specific and developmentally regulated alpha7 integrin gene promoter. J Biol Chem 1996; 271: 22915-22922.

GO BACK to the 2014, October-December issue
GO BACK to DISCOVERIES 
MEET OUR EDITORIAL BOARD 
SUBMIT A MANUSCRIPT

Email Email us at info@discoveriesjournals.org if you have any questions.

News & Events Latest news from Discoveries

  • 2018 | For Authors!

    PMC highlighted that a high proportion of authors of Discoveries articles are also members of our Editorial Board. As a result, from now on and for at least 1 year, we will only accept articles from authors that are NOT members of Discoveries' Editorial Board. All articles submitted by our members will be immediately rejected until further notice (one accepted article was already rejected). 

  • 2017-2018 | PubMed inclusion News!

    Discoveries successfully passed the Scientific Quality Review by NLM-NIH for PubMedCentral and PubMed indexing. This is the first and the most important step towards PubMedCentral and PubMed indexing! The second (last) step is the Technical Review.

  • April 2016 | Faster Peer-Review

    Starting on April 13th 2016, all articles selected for a peer-review will receive the post peer-review decision within 10 days. The initial pre-screening time will remain the same (48h from the submission of the manuscript). This decision will significantly accelerate the publication, with no effect on the quality of the peer-review process.

  • February 2016 | Manuscript submission

    Discoveries is commited to excellence, quality and high editorial standards. We are receiving an increasing number of manuscripts for which the identity of the authors/corresponding author can't be verified. Please NOTE that ALL these articles were and will be immediately REJECTED. Indicating an institutional email address is the easiest way to overcome this problem! Moreover, we do not accept any pressure on our editorial board to accept a manuscript. This results in a prompt rejection of the article.

    Editorial Policies
  • January 2016 | Main Objective

    After reaching all proposed milestones until now (including being indexed by Google Scholar in 2014), Discoveries' next Aim is PubMed indexing of all its articles (already published and upcoming). There will be no charge for the submission or publication of articles before Discoveries is indexed.

  • August 2015 | Discoveries - on PubMed

    We are happy to announce that our first Discoveries articles were included in PMC and PubMed. More articles (submitted by NIH funded authors) are now processed for being included.

    Discoveries articles now on PubMed
  • April 2015 | Special Issue

    DISCOVERIES published the SPECIAL ISSUE entitled "INFLAMMATION BETWEEN DEFENSE AND DISEASE: Impact on Tissue Repair and Chronic Sickness".

    Special Issue on "Inflammation"
  • 2015 | Ischemia Collection

    DISCOVERIES launched a call for papers for a Collection of Articles with focus on "ISCHEMIA". If you are interested to submit a manuscript, please contact us at info@discoveriesjournals.org

  • September 2014 | Special Issue

    DISCOVERIES just publish the SPECIAL ISSUE entitled "CELL SECRETION & MEMBRANE FUSION" in September 2014. Initially scheduled for publication between October 2014-March 2015, this issue was successfully published earlier than scheduled. 

    Special Issue
  • April 2014 | Indexed by Google Scholar

    All our published articles are now indexed by Google Scholar! First citations to Discoveries articles are included! Search for the article's title (recommended) or the authors:

    Google Scholar Search
  • 2014 | DISCOVERIES

    DOIs (Digital Object Identifiers) are now assigned to all our published manuscripts in Discoveries. DOI uniquely identifies an article and is provided by CrossRef.

    CrossRef
  • July 2013 | Manuscript Submission

    Submit your manuscript FREE, FAST and EASY ! (in less than 1 minute)! There are NO fees for the manuscript submission or publishing of the accepted manuscripts.
    read more

  • July 2013 | DISCOVERIES

    We are now ACCEPTING MANUSCRIPTS for publishing in DISCOVERIES. We aim publishing a small number of high impact experimental articles & reviews (around 40/year) to maintain a high impact factor. Domains of interest: all areas related to Medicine, Biology and Chemistry ...

    read more
Member Login
Free Registration Click here to sign up
Copyright © 2013 Applied Systems. All Rights Reserved.